Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07643961
Outpatient Versus Inpatient Management of Mild Acute PancreatitisCenter for Traumatology and Major Burns, Ben ArousNot Yet RecruitingNot Applicable
NCT07643961Not Yet Recruiting
Not Applicable
Outpatient Versus Inpatient Management of Mild Acute PancreatitisCenter for Traumatology a...
NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D CompanyNot Yet RecruitingPhase 1
NCT07645222Not Yet Recruiting
Phase 1
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D Com...
NCT07646223
Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisFimlab laboratoriesNot Yet RecruitingPhase 2
NCT07646223Not Yet Recruiting
Phase 2
Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisFimlab laboratories
NCT07644338
The Efficacy and Safety of Temporal Interference Stimulation in the Treatment of Post-Traumatic Stress DisorderShanghai Mental Health CenterRecruitingNot Applicable
NCT07644338Recruiting
Not Applicable
The Efficacy and Safety of Temporal Interference Stimulation in the Treatment of...Shanghai Mental Health Ce...
NCT07645664
Scar Management Through Serial CastingCentre hospitalier de l'Université de Montréal (CHUM)Not Yet RecruitingNot Applicable
NCT07645664Not Yet Recruiting
Not Applicable
Scar Management Through Serial CastingCentre hospitalier de l'U...
NCT07645586
A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic StrokeBeijing Tiantan HospitalNot Yet RecruitingPhase 3
NCT07645586Not Yet Recruiting
Phase 3
A Phase 3 Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After A...Beijing Tiantan Hospital
NCT07644169
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG) in Healthy Adults Following PG ExposureAmerican Beverage AssociationNot Yet RecruitingNot Applicable
NCT07644169Not Yet Recruiting
Not Applicable
A Clinical Trial to Assess the Pharmacokinetic Profile of Propylene Glycol (PG)...American Beverage Associa...
NCT07645768
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alternative to Conventional Posterior Double Plating in Extra-Articular Distal Shaft Humeral FracturesCairo UniversityActive Not RecruitingNot Applicable
NCT07645768Active Not Recruiting
Not Applicable
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alter...Cairo University
NCT07644780
Evaluation of an Intervention for Optimizing Pregnant Women's Adherence to Maternal Multiple Micronutrients SupplementsNutrition InternationalCompletedNot Applicable
NCT07644780Completed
Not Applicable
Evaluation of an Intervention for Optimizing Pregnant Women's Adherence to Mater...Nutrition International
NCT07645105
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or ObesityMedical University of SilesiaCompleted
NCT07645105Completed
—
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obes...Medical University of Sil...
NCT07645027
Low Volume Nose Resistance Breathing Exercise With Incentive Spirometer in Patient With Cervical Spinal Cord InjuriesRiphah International UniversityRecruitingNot Applicable
NCT07645027Recruiting
Not Applicable
Low Volume Nose Resistance Breathing Exercise With Incentive Spirometer in Patie...Riphah International Univ...
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07645690
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell CarcinomaChinese PLA General HospitalRecruitingEarly Phase 1
NCT07645690Recruiting
Early Phase 1
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Meta...Chinese PLA General Hospi...
NCT07646366
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee OsteoarthritisRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646366Not Yet Recruiting
Not Applicable
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee O...Riphah International Univ...
NCT07645248
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)GlaxoSmithKlineNot Yet RecruitingPhase 3
NCT07645248Not Yet Recruiting
Phase 3
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1...GlaxoSmithKline
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646561
Transcranial Doppler in Preeclampsia and Its Complications.University Tunis El ManarCompleted
NCT07646561Completed
—
Transcranial Doppler in Preeclampsia and Its Complications.University Tunis El Manar
NCT07645235
A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating WomenBiomedical Advanced Research and Development AuthorityNot Yet RecruitingPhase 1
NCT07645235Not Yet Recruiting
Phase 1
A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Wom...Biomedical Advanced Resea...
NCT07644403
Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors.Suzhou Immunofoco Biotechnology Co., LtdEnrolling By InvitationPhase 1
NCT07644403Enrolling By Invitation
Phase 1
Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid...Suzhou Immunofoco Biotech...
Result Breakdown
Not yet recruiting10 (50%)
Recruiting5 (25%)
Completed3 (15%)
Active, not recruiting1 (5%)
Enrolling by invitation1 (5%)
not_applicable8 (40%)
Phase 14 (20%)
Not Specified3 (15%)
Phase 22 (10%)
Phase 32 (10%)
Early Phase 11 (5%)